 |
Presenter |
| Presenter | see Discussant report |
 |
Steg, Philippe Gabriel
(France) |
|
|
List of Authors:
STEG, Philippe Gabriel; ALAM, S; CHIANG, CE; GAMRA, Habib; GOETHALS, M; INOUE, H; LEWALTER, Thorsten; MURIN, Jan; O'Neill, J; PONIKOWSKI, Piotr
Abstract:
Purpose:
The epidemiology and management of atrial fibrillation (AF) vary according to geography, prevalence and type of comorbidities, physician specialties, and types of AF. Most of the data available pertain to North America and Western Europe.
Methods:
The REALISE-AF registry is an international cross sectional registry of AF: Approximately 10,000 patients with history of AF (treated or not and whatever the rhythm at inclusion) with at least one AF episode documented by standard ECG or by ECG-Holter monitoring in the last 12 months, or documented current AF, are being recruited from 859 sites in 26 countries on 4 continents. Participating physicians were randomly selected among a global list of office-based or hospital-based cardiologists and internists, on the basis of epidemiologic data regarding local practice. Patient information is collected using a centralized case report form and includes baseline characteristics, symptoms, prior tests, ECG data, medical history and risk factors, medications, history and characteristics of AF, management of AF, in term of strategy chosen (rate vs. rhythm control) , antiarrhythmic drugs,, and/or rate control agents chosen, use of antithrombotics (in relation to CHADS2 score) and consistency with international guidelines. In addition, the registry will assess health-related quality of life (QoL) (using the validated EQ-5D tool). Physician information at each site is also collected. Primary analyses include frequency of AF control (ie achieving either sinus rhythm or resting HR <80 bpm) and description of cardiovascular (CV) risk. Secondary analyses include relationship between AF control and cardiovascular risk factors, as well as assessment of other AF-related CV endpoints, and health-related QoL.
Results:
Data collection ends in March 2010 and results will be available for presentation in late August. This presentation will be the first disclosure of the results worldwide.
Conclusion:
RealiseAF is the 1st global, observational, cross-sectional registry to provide information on all AF types, associated CV risk and subsequent therapeutic decisions.